To review recent studies reporting toxicity, adverse events, side effects, and drug–drug interactions related to the use of HIV protease inhibitors, with particular focus on possible clinical implications.
Toxicity-associated adverse events still remain a major concern when prescribing HIV protease inhibitors. Among those, diarrhea, lipid, and liver enzyme elevations are predominant. Also, with protease inhibitors being metabolized by the hepatic cytochrome P450, a significant number of drug–drug interactions has to be taken into account in patients who often require coadministration of drugs to treat supplementary diseases, for example, tuberculosis. Hence, scientific interest in this area continues to be high, especially in characterizing individual toxicities of particular protease inhibitors as well as in comparing them among each other.
Protease inhibitors are still a cornerstone of combination antiretroviral therapy. A profound knowledge of the unwanted, but manageable, effects of protease inhibitor therapy is required to maintain an otherwise efficient and well tolerated antiretroviral therapy. Further research will elucidate the potential role of protease inhibitors both in double-boosted salvage therapy and in resource-limited settings.
aNational Centre in HIV Epidemiology and Clinical Research, Australia
bCentre for Immunology, St. Vincent's Hospital, University of New South Wales, Sydney, Australia
Correspondence to Dr Christoph Boesecke, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia Tel: +61 2 9385 0900; fax: +61 2 9385 0910; e-mail: email@example.com